ReviewJPRAS open2026
Surgical management of plexiform neurofibromas: An imaging-based perioperative framework.
Review in JPRAS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plexiform neurofibromas (PNs) are complex, infiltrative peripheral nerve sheath tumors affecting up to half of individuals with neurofibromatosis type 1 (NF1). Their diffuse, multicompartment growth, potential for disfigurement and neurologic compromise, and elevated risk of malignant peripheral nerve sheath tumor make management uniquely challenging. Optimal care hinges on accurate imaging, multidisciplinary planning, and strategic selection between complete resection and function-preserving debulking. MRI is central to perioperative assessment, with whole-body MRI supporting baseline mapping and regional MRI providing high-resolution definition for operative planning. Angiographic studies assist in identifying candidates for preoperative embolization, while FDG-PET improves detection of distinct nodular lesions and atypical neurofibromas with higher malignant potential. Preoperative embolization may reduce intraoperative hemorrhage in highly vascular PNs. Surgical indications include progressive neurologic deficits, airway or organ compromise, refractory pain, and severe disfigurement. Complete resection offers maximal oncologic control but risks permanent deficits; subtotal or debulking procedures prioritize function preservation while accepting recurrence risk. Adjuncts such as fluorescein-guided resection, intraoperative neurophysiological monitoring, and 3-dimensional planning enhance precision and safety. Reconstruction requires site-specific strategies for head and neck, truncal, and extremity lesions. Postoperatively, MRI-based surveillance is critical, particularly following subtotal resection or in high-risk anatomical locations. MEK inhibitors, including selumetinib, provide effective non-surgical therapy for progressive or unresectable PNs. Management of PNs demands individualized, multidisciplinary care. An imaging-driven approach, selective use of embolization, and incorporation of intraoperative adjuncts can optimize tumor control and functional outcomes. Prospective multicenter studies are needed to standardize imaging protocols, surgical selection criteria, and long-term outcome reporting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.